Go Pro
→ “Elon Is Not Showing This Publicly, But I Saw It” (From Brownstone Research) (Ad)tc pixel Free TCRX Stock Alerts

TScan Therapeutics (TCRX) Competitors

TScan Therapeutics logo
$0.33 +0.02 (+6.00%)
As of 09/21/2026 04:00 PM Eastern
Compare

TCRX vs. CTOR, TELO, ACRV, SERA, and KLRS

Should you buy TScan Therapeutics stock or one of its competitors? TScan Therapeutics's main competitors and comparable companies include Citius Oncology (CTOR), Telomir Pharmaceuticals (TELO), Acrivon Therapeutics (ACRV), Sera Prognostics (SERA), and Kalaris Therapeutics (KLRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TScan Therapeutics compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Citius Oncology has a beta of 3.52, indicating that its stock price is 252% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Citius Oncology has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Citius Oncology's return on equity of -102.98% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius OncologyN/A -102.98% -43.49%
TScan Therapeutics -1,655.35%-108.72%-54.47%

Citius Oncology has higher earnings, but lower revenue than TScan Therapeutics. Citius Oncology is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius OncologyN/AN/A-$24.76M-$0.47N/A
TScan Therapeutics$10.32M2.17-$129.77M-$0.91N/A

Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 474.16%. TScan Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 706.61%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Citius Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Oncology
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
TScan Therapeutics
1 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.13

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, TScan Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 1 mentions for TScan Therapeutics and 0 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.00 equaled TScan Therapeutics'average media sentiment score.

Company Overall Sentiment
Citius Oncology Neutral
TScan Therapeutics Neutral

Summary

Citius Oncology beats TScan Therapeutics on 8 of the 13 factors compared between the two stocks.

How does TScan Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Telomir Pharmaceuticals had 5 more articles in the media than TScan Therapeutics. MarketBeat recorded 6 mentions for Telomir Pharmaceuticals and 1 mentions for TScan Therapeutics. Telomir Pharmaceuticals' average media sentiment score of 0.31 beat TScan Therapeutics' score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telomir Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
TScan Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Telomir Pharmaceuticals has higher earnings, but lower revenue than TScan Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.91N/A
TScan Therapeutics$10.32M2.17-$129.77M-$0.91N/A

Telomir Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

82.8% of TScan Therapeutics shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Telomir Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Telomir Pharmaceuticals' return on equity of -102.70% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -102.70% -90.75%
TScan Therapeutics -1,655.35%-108.72%-54.47%

Telomir Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 222.58%. TScan Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 706.61%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Telomir Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
TScan Therapeutics
1 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

Telomir Pharmaceuticals beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Acrivon Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

TScan Therapeutics currently has a consensus target price of $2.67, indicating a potential upside of 706.61%. Acrivon Therapeutics has a consensus target price of $13.50, indicating a potential upside of 571.64%. Given TScan Therapeutics' higher probable upside, research analysts clearly believe TScan Therapeutics is more favorable than Acrivon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TScan Therapeutics
1 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.13
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Acrivon Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Acrivon Therapeutics' return on equity of -70.14% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TScan Therapeutics-1,655.35% -108.72% -54.47%
Acrivon Therapeutics N/A -70.14%-61.60%

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Acrivon Therapeutics had 3 more articles in the media than TScan Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 1 mentions for TScan Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.43 beat TScan Therapeutics' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TScan Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Acrivon Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Acrivon Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TScan Therapeutics$10.32M2.17-$129.77M-$0.91N/A
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A

TScan Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Summary

Acrivon Therapeutics beats TScan Therapeutics on 9 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 159.43%. TScan Therapeutics has a consensus price target of $2.67, indicating a potential upside of 706.61%. Given TScan Therapeutics' higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sera Prognostics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
TScan Therapeutics
1 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.13

TScan Therapeutics has a net margin of -1,655.35% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sera Prognostics-47,475.72% -46.71% -34.06%
TScan Therapeutics -1,655.35%-108.72%-54.47%

In the previous week, Sera Prognostics and Sera Prognostics both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.00 equaled TScan Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sera Prognostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TScan Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sera Prognostics has higher earnings, but lower revenue than TScan Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sera Prognostics$80K1,045.43-$31.93M-$0.67N/A
TScan Therapeutics$10.32M2.17-$129.77M-$0.91N/A

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sera Prognostics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Summary

Sera Prognostics beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Kalaris Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Kalaris Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Kalaris Therapeutics' return on equity of -71.71% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TScan Therapeutics-1,655.35% -108.72% -54.47%
Kalaris Therapeutics N/A -71.71%-42.95%

TScan Therapeutics currently has a consensus price target of $2.67, indicating a potential upside of 706.61%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 478.70%. Given TScan Therapeutics' higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Kalaris Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TScan Therapeutics
1 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.13
Kalaris Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TScan Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Kalaris Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TScan Therapeutics$10.32M2.17-$129.77M-$0.91N/A
Kalaris TherapeuticsN/AN/A-$43.44M-$2.02N/A

In the previous week, TScan Therapeutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for TScan Therapeutics and 0 mentions for Kalaris Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company Overall Sentiment
TScan Therapeutics Neutral
Kalaris Therapeutics Neutral

Summary

TScan Therapeutics and Kalaris Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRX vs. The Competition

Export
MetricTScan TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21.14M$3.90B$7.25B$12.97B
Dividend YieldN/A3.64%2.53%12.80%
P/E Ratio-0.3614.12274.7125.77
Price / Sales2.171,420.48696.46109.69
Price / CashN/A41.6228.0434.72
Price / Book0.1515.6010.566.36
Net Income-$129.77M-$22.86M$3.49B$358.17M
7 Day Performance2.89%0.81%0.80%1.60%
1 Month Performance-57.59%-4.59%-2.80%-2.97%
1 Year Performance-81.43%34.78%16.68%5.63%

TScan Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRX
TScan Therapeutics
2.6722 of 5 stars		$0.33
+6.0%		$2.67
+706.6%		-81.5%$21.14M$10.32MN/A142
CTOR
Citius Oncology
1.3698 of 5 stars		$0.88
-6.0%		$6.00
+578.7%		-40.6%$81.17M$7.11MN/AN/A
TELO
Telomir Pharmaceuticals
1.8174 of 5 stars		$1.18
+0.9%		N/A-19.0%$81.15MN/AN/A1
ACRV
Acrivon Therapeutics
3.8695 of 5 stars		$1.84
-6.4%		$13.50
+635.7%		+23.3%$78.64MN/AN/A58
SERA
Sera Prognostics
1.9271 of 5 stars		$1.98
-1.0%		$5.50
+177.8%		-35.8%$78.11M$70KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 9/22/2026 by MarketBeat.com Staff.
From Our Partners
A councilman backed AI — then 13 bullets hit his front door
Thirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...
Stansberry Research | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
“Elon Is Not Showing This Publicly, But I Saw It”
Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown,...
Brownstone Research | Sponsoredtc pixel
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel